Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

HIV Remission After Allogeneic Stem Cell Transplantation: Conclusions From 10 Successful Cases.

Created on 07 Oct 2026

Authors

Kristina Allers, Christian Gaebler, Thomas Schneider

Published in

Deutsches Arzteblatt international. Volume 123. Issue 25. Dec 11, 2026. Epub Dec 11, 2026.

Abstract

Approximately 100 000 people in Germany are now living with human immunodeficiency virus (HIV), with 2300 new cases per year. A cure for HIV infection was long considered unattainable. The first patient to achieve sustained HIV remission after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was treated in Berlin, providing proof of principle. In this review, we summarize the cases of sustained HIV remission after allo-HSCT published to date and classify them with regard to possible underlying mechanisms. We also discuss the prospects for future curative strategies.
This review is based on relevant publications retrieved by searches in PubMed and the international IciStem database, as well as the authors' longstanding scientific experience and international scientific exchange. Published cases of sustained HIV remission after allo-HSCT and discontinuation of ART were included in the review.
After the initial patient in Berlin, nine further cases of sustained HIV remission after allo-HSCT have been reported to date. Eight of the ten patients received donor cells with a homozygous 32-base-pair deletion in the gene for the C-C chemokine receptor type 5 (CCR5Δ32/Δ32), which leads to loss of the CCR5 receptor on the cell surface and thus resistance to CCR5-tropic HIV variants. In the other two patients, sustained remission was achieved without the homozygous mutation: The Geneva patient received wild-type CCR5 donor cells, and the second Berlin patient received cells from a heterozygous donor (CCR5WT/Δ32).
These cases demonstrate that allo-HSCT can lead to sustained remission. Along with the approach used in SHIV-infected monkeys, in which remission was achieved by inducing anti-CCR5 autoantibodies, they yield insights into strategies beyond allo-HSCT.

PMID:
42839696
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement